Trends in the global immuno-oncology landscape

  • An Erratum to this article was published on 26 October 2018

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Trends in the global IO pipeline.
Figure 2: Trends in IO targets.
Figure 3: Trends in organizations with IO agents in clinical development.

Change history

  • 26 October 2018

    In the original version of Figure 1, the label on the y axis 'T cell-targeted' was incorrect and should be 'T cell-targeted immunomodulator'. The article has been corrected in the online version.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jun Tang.

Ethics declarations

Competing interests

J.O-T. is a paid board member of HemaCare. L. P. is a consultant to Cancer Research Institute and Canadian Cancer Trials Group.

Related links

PowerPoint slides

Supplementary information

Supplementary information

Supplementary Table (XLSX 23 kb)

Supplementary information

Trends of TAA-targeted IO agents in the past year. (PDF 183 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tang, J., Pearce, L., O'Donnell-Tormey, J. et al. Trends in the global immuno-oncology landscape. Nat Rev Drug Discov 17, 783–784 (2018). https://doi.org/10.1038/nrd.2018.167

Download citation

Further reading